A research grant to investigate the potential of a novel type of “personalised cellular therapy” to reverse the ultra-rare condition, aplastic anaemia
Brain health company IXICO launched a digital platform, Project Cygnus, to support patients with the diseases that cause dementia. IXICO is the lead partner in the project, working alongside MRC Technology, The Northern Health Science Alliance Network (NHSA) and several NHS Trusts in the North of England. The project is part-funded by Innovate UK (formerly the Technology Strategy Board).
The Neurodegeneration Medicines Acceleration Programme (Neuro-MAP), led by medical research charity MRC Technology, will see charities and funding bodies identify promising drug projects no longer in development and help scientists to take them forward to the next stage. Drugs for brain diseases such as dementia, motor neurone disease and Parkinson’s could be revived.
The initiative will focus on identification of novel druggable targets in the field of small molecules and antibodies, and collaborating to fast track those targets through drug discovery to create potent and selective novel therapeutics. It brings together EMBLEM’s experience in supporting academics in one of the world’s leading locations for scientific research, with MRC Technology’s dedicated expertise in translating novel biology targets into lead stage therapeutic assets.
MRC Technology's Director of Drug Discovery, Justin Bryans, is quoted in a Nature Biotechnology article about the…